Anaplastic Astrocytoma Drug Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2027
The global anaplastic astrocytoma drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anaplastic astrocytoma is a rare type of brain tumor that starts from brain cells called astrocytes. Astrocytes are a type of glial cell. Additionally, it is both a type of astrocytoma and high-grade glioma. The major factor driving the growth of the market is the increasing prevalence of anaplastic astrocytoma across the globe.
According to the National Organization for Rare Diseases, astrocytomas are
the most common primary brain tumors. It affects males more often than females
and is estimated to affect 5-8 people per 100,000 in the general population.
Additionally, anaplastic astrocytomas are more common in adults than children
and usually develop between 30 and 50 years of age in adults. Furthermore,
anaplastic astrocytomas usually develop between 5 and 9 years of age in
children and account for approximately 10% of childhood central nervous stem
tumors. Moreover, approximately 80% of astrocytomas in children are low grade.
Hence, the increasing prevalence of anaplastic astrocytoma is driving the
demand for anaplastic astrocytoma drugs for treatment which in turn is driving
the growth of the market.
To Request a Sample of our Report on Anaplastic
Astrocytoma Drug Market: https://www.omrglobal.com/request-sample/anaplastic-astrocytoma-drug-market
Some major players in the market
include Amgen Inc, Astellas Pharma Inc., and Bayer AG, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in January 2021,
Adastra Pharmaceuticals, Inc. announced the completion of the Phase 1b clinical
trial conducted by the NCI with its lead clinical candidate zotiraciclib
(ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. The trial
was aimed to investigate the safety and efficacy of ZTR in combination with
temozolomide (TMZ) in patients with recurrent high-grade gliomas.
Market
Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment
Covered-
·
By Type
·
By Application
Regions
Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Amgen Inc, Astellas Pharma Inc., and Bayer
AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Anaplastic Astrocytoma Drug Market is Available @ https://www.omrglobal.com/industry-reports/anaplastic-astrocytoma-drug-market
Global Anaplastic Astrocytoma Drug Market Report by
Segment
By
Type
•
A-10
•
AS-21
•
AdRTSIL-12
•
ADU-623
•
Others
By
Application
•
Hospital
•
Clinic
•
Others
Global
Anaplastic Astrocytoma Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment